https://medicaldialogues.in/news/industry/pharma/takedas-exkivity-mobocertinib-approved-by-us-fda-as-the-first-oral-therapy-specifically-designed-for-patients-with-egfr-exon20-insertion-nsclctakeda-gets-usfda-nod-for-cancer-treatment-exkivity-82081